Thrombolytic Therapy in the Oldest Old: Successful Alteplase Administration in a 105-Year-Old Female With Ischemic Stroke
- PMID: 34909307
- PMCID: PMC8653926
- DOI: 10.7759/cureus.19346
Thrombolytic Therapy in the Oldest Old: Successful Alteplase Administration in a 105-Year-Old Female With Ischemic Stroke
Abstract
The elderly have a higher incidence of ischemic stroke along with higher mortality and morbidity compared to their younger counterparts. However, though studies have included people >85 or 90 years of age, there haven't been reports of many individuals above 100 years of age. Among the oldest old, the oldest age studied for alteplase administration is possibly 101 years. We present a case of a 105-year-old woman with a medical history of a cerebrovascular accident in 2018 for which she received thrombolytic therapy with residual slurred speech and mild dysphagia. She was brought in from her nursing facility for worsening of slurred speech and right facial droop that began two hours before presentation to the emergency department. She was found to have aphasia, left-sided gaze preference, and upper motor neuron dysfunction of her right arm associated with drift. Her National Institutes of Health Stroke Scale (NIHSS) score at presentation was 17. An urgent CT scan of the head was performed that did not show any evidence of acute bleeding. CT angiogram of brain and neck was unremarkable with no evidence of high-grade stenosis, aneurysm, occlusion, or dissection. With the negative CT findings, the patient received thrombolytic therapy with alteplase. She was monitored in the intensive care unit for 24 hours after alteplase administration with neurological checks every one hour. The repeated CT head after 24 hours was negative for any hemorrhage. She was discharged after two days of hospital admission and her NIHSS score on the day of discharge was 4. Our patient was 105 years old, which is arguably one of the oldest ages to receive alteplase. Her NIHSS score improved considerably and she did not suffer from hemorrhagic complications.
Keywords: 105 year old and alteplase; alteplase; alteplase in elderly; oldest old and thrombolysis; stroke in elderly; tissue plasminogen activator (tpa); tpa in elderly.
Copyright © 2021, Bhandari et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
References
-
- Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-arterial thrombolysis for acute stroke. Pundik S, McWilliams-Dunnigan L, Blackham KL, et al. J Stroke Cerebrovasc Dis. 2008;17:266–272. - PubMed
-
- The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Sandercock P, Wardlaw JM, Lindley RI, et al. Lancet. 2012;379:2352–2363. - PMC - PubMed
-
- The population 65 years and older in the United States: 2016. Roberts AW, Ogunwole SU, Blakeslee L, Rabe MA. https://www.census.gov/content/dam/Census/library/publications/2018/acs/... States. 2018:38.
-
- Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Stroke. 2016;47:581–641. - PubMed
Publication types
LinkOut - more resources
Full Text Sources